Interview: Medtronic CEO Ishrak on the road ahead


When last spoke with Omar Ishrak, the CEO of the world’s largest pure-play medical device company, he detailed a trio of goals for Medtronic (NYSE:MDT) designed to remake the company after his own image: Better execution, optimized innovation and a larger share of the global medtech business.

When we sat down with Ishrak this morning at the J.P. Morgan healthcare conference in San Francisco, there was little outward difference. But Medtronic has undergone substantial internal change on his watch, he explained, as his initiatives have aligned the company’s goals.

In a wide-ranging chat that covered the 1st 18 months of his time in the corner office, the climate for medtech investment, the FDA and the medical device tax, Ishrak said Medtronic has made a lot of progress, but stressed that there’s still a lot more to be done. What follows is an edited transcript of our conversation. At last year’s conference, you outlined 3 priorities for 2012: Improving execution, optimizing innovation and accelerating the spread of your global footprint. You also stressed the importance of moving with speed and agility. How would you rate your progress in executing toward those goals during the past year?

Omar Ishrak: We made a lot of progress in the last year and in some ways we’ve reoriented the company in a little more strategic fashion. Those goals that were outlined were more operational priorities, and they remain, but we have also now, ever since our analysts’ meeting in June, rolled out a mid-term strategy and a long-term strategy for the company, baseline expectations of performance and long-term aspirations.

What remains constant in all of this is our ability to execute. I’d say that in the last 18 months since I’ve joined the company, we’ve had steady progress, we’ve by and large hit our external expectations in terms of what we said we were going to do. We’ve certainly hit our guidance for last fiscal year.

The 3 main reasons the execution performance is showing some improvement is primarily because the alignment of the team, the operational rigor and structure that was put in place soon after I joined, is having an impact in clearing priorities for the team and people working with each other in a complementary fashion. The management team is working together pretty cohesively now.

The 2nd reason is the products that were launched, 1st were launched more or less on time across the board. But more important than that, they have been successful commercially. So it’s not only the timely execution of new product launches, but that the conversion of new products into revenue that met or exceeded our expectations was obviously a very important factor in our ability to deliver performance.

The 3rd item is tied to the 1st one – a deeper level of accountability across the business in taking responsibility for our own performance, optimizing things that we can control and not blaming things we cannot control. Things like that happen, but by and large it’s just a mindset. We’ve got a lot of variables that we can control. [The economy] is an easy one to throw out there. But if there isn’t any opportunity in healthcare, where is there? People will need better healthcare across the world. If we can’t turn that into a business model for us, that’s our problem. That mindset changing was very important.

Having said that, we’ve got to show performance on a sustained basis over a much longer period of time, to win credibility externally and feel good about it ourselves. This is very early progress – obviously we’re somewhat pleased with what we’ve gotten so far, but we’ve got a long way to go.

In terms of globalization, continuing on the theme from last year, we solidified out strategies and understanding, with more granularity, of what the opportunities are in each country.

We certainly see a goal of doubling our exposure to emerging market business within the next several years. It was 10% in FY 2011; we want to take that up to 20% over the next couple of years. The point is that emerging markets are growing faster; soon they will occupy a bigger portion of our business.

Finally, on innovation, while talking about innovation last year we didn’t talk about economic value. We’ve really firmed up economic value as being one of the major thrusts that the company will have to make in the next several years – and eventually it will transform the company. Economic value, in simple terms, is projecting our value proposition in financial terms for our customers. So not only the clinical benefits, but the financial benefits of what we offer.

This is particularly challenging, because the cost of healthcare is incurred during a procedure. The benefit of that investment, if you like, is realized at later time and potentially in a different place. As a result, one can never really truly understand the costs. This open-loop approach to healthcare where the costs and benefits are not measured concurrently leads to more costs and an inefficient use of healthcare. It’s seen as a cost, rather than as an investment, when in fact it is an investment. There’s no question that this has to be addressed for healthcare costs to come down to a reasonable level without rationing, which is not the right thing to do.

We want to take a leadership position in this journey by working in a very granular fashion, identifying where the financial benefits are for our technologies and identifying them to our customers. If we’re successful in doing that, we feel we can get a disparate share of the market, because the value proposition is obvious to them.

We’re working with major hospital systems to run pilots to show benefits to their financial systems. Once those pilots are successful, we intend to scale them across those systems and eventually do even broader market expansion. In addition to that, for future products and across our entire business, we’re asking the questions about economic value before we spend any money on products. This whole approach is changing, to a large degree, the mindset and the thinking and the culture in the company. Clearly China has been a focus of your tenure, with the Kanghui acquisition and deployment of significant resources there. How do you plan to build on the foundation there, and where else in the emerging world captures your attention?

OI: We’ve made significant investments in China and we continue to do that. The point about all markets is that every country is different and healthcare systems are different, the capacity and the culture within the country. We need to have strategies that are unique to those regions. In all cases, we’ve found that the opportunity among people who can afford the treatments we have today is enormous.

Kanghui and LifeTech are long-term growth strategies. Overnight, after the acquisition of Kanghui, our scale and critical mass in understanding the needs of the Chinese customer improved by orders of magnitude. We now have north of 50 engineers in Kanghui who spent a decade looking at the very specific needs of Chinese patients, in spine and trauma and so on. That expertise in a market that has a much larger population than in the West creates a platform for us that we think will be a long-term growth vehicle. What’s your take on the funding environment? The economy seems to be recovering slowly and the VC community is still stepping cautiously when it comes to medtech. Do you see the chance for more VC investment this year? Or will smaller players turn to strategics, as many did last year, to gain the capital they need to develop new products?

OI: This is just an opinion, because were much more focussed on our own growth strategies. The clinical trial process and the regulatory process puts a constraint on how far smaller companies can go and how willing VCs are to fund them – because the time-frame for returns is much longer. I think that’s going to continue, to some degree. We need to make that process more efficient, but I think the extent of clinical trials is probably correct for safety purposes.

It’s not that [smaller companies] will go away; it’s just that there’ll be a much tighter selection mechanism. I think these things will work themselves out. If people have good ideas, they’ll find ways to get them out there. Maybe the screen on a good idea, the mesh is little finer, but if it’s a really good idea it will succeed. How would you grade the FDA’s performance under the Obama administration? Is there more certainty around the regulatory climate, in your view?

OI: The FDA has made a real effort in working with industry to speed up the process, while making sure safety is correctly monitored. I think they’ve made a real effort to be transparent and reached out to work in collaboration with industry, to make sure we do trials and so on properly. We’ve been appreciative of the efforts they’ve made to reach out to us. In addition, they’re very open in looking at post-market surveillance methods. Hopefully we can work in an increasingly collaborative fashion. I think we’re making progress, I really do. There’s a genuine effort to speed things up. How will Medtronic deal with the medical device tax, with hospitals already pushing back hard on pricing? What about its impact on the M&A scene? The tax will hit smaller companies who are just starting to commercialize – could that drive more M&A from the large-cap players?

OI: The tax affects everybody. We may have more capital, but believe it or not, it’s all used up. So this is extra money.

It affects everyone, not just small companies. I’m not sure that this is that big a variable, compared to the length of clinical trials. That’s a much bigger item than this. This is really small compared to that. It’s more or less known, it’s a known amount that can be quantified and once people have done that they can get over it. I’m not sure, from an M&A perspective or from a small company pressure perspective, that this is anywhere close to the clinical process. The Infuse situation seems to have a life of its own, with even the U.S. Senate getting involved. The Senate report accused Medtronic of deliberately obscuring evidence of adverse events, promoting off-label use and manipulating study reports via payments to participating physicians. How do you respond to those charges?

OI: A lot of things have happened since then. We have transformed the spine business and our ethics right now are very high. Our standards are high, in terms of the way we do things. I don’t want to dig up the past here, but we feel that, by and large, we’ve done the right thing in the past. And certainly right now we’ve got very rigorous procedures in place, so we’re very confident about where the business stands today.

The U.S. Justice Dept. investigation is closed and that gives us some assurance that the actions that we’re taking are being noticed. But more important than that, from a process and procedure perspective, we intend to be transparent and we intend to work in the most ethical fashion possible in collaboration with our partners.

There’s no room for anyone in the company to cross the line on that. Our integrity and patient safety are our highest priorities in everything we do. I hold that personally very high on my value system.

Aside from that, the point is that allegations were made about usage of the product and its safety. We obviously have to take that very seriously. There wasn’t any hard evidence that anyone could act on. The only way to resolve this was to commission a completely independent study that would get the facts. That process takes some time, because it’s an academic process. People have gone through the data and written some manuscripts, which the steering committee has looked at. They’re in the process of publishing that. Right now we’re still looking at a few months away before something’s published. I think that will clarify things. Remember, this will be data, this will be academic, so there’s not going to be "yes or no" stuff here, but it will be data and people can make their on conclusions based on that. And so will we.

Right now, frankly, the Infuse business has declined significantly in the last year as a result of this uncertainty. The rate of decline has decreased, but in the last quarter, for example, it was still down. We want to do the right thing. There’s a lot of value in the product, but patient safety is more important than that. But patient safety cuts both ways – if there’s value in the product and it helps people, we want to make sure its available.

RSS From Medical Design & Outsourcing

  • 3-phase current transducer from PEM delivers all-in-one convenience
    The new RCTrms 3-ph current transducer from Power Electronic Measurements (PEM) delivers a convenient, safe and accurate solution for measuring current in three phases. It features a thin, clip-around, flexible sensor coil and provides accurate true rms measurement with 4-20 mA or 0-5 V output, enabling simple installation with PLC’s, SCADA systems or automation equipment. […]
  • Safety alert: Recall on two IV solutions from Baxter
    Baxter International announced it is voluntarily recalling two lots of intravenous (IV) solutions to the hospital and user level due to the potential presence of particulate matter. The particulate matter in each case was determined to be an insect and was identified as a result of a customer complaint. The matter was identified prior to […]
  • TSO3 begins shipment of STERIZONE VP4 Sterilizers to U.S.
    TSO3, a developer in sterilization technology for medical devices in healthcare settings, announced that the company has received purchase orders for multiple devices from the U.S. The orders are the result of the collaborative relationship between Getinge Infection Control, its sales and service provider, and TSO3. “Finally,” said R.M. Rumble, president and CEO of TSO3. “Our Vision is […]
  • Turkish medical company is seeking reseller and OEM partners in the U.S.
    UZUMCU Medical Equipment, one of Turkey’s first and largest manufacturers of medical devices, is seeking reseller and OEM partners in the U.S. The company has an array of FDA-certified OR tables, surgical lights, surgical suction units, electro devices and other medical equipment. “We want to bring our experience with distributors throughout Europe and the Middle […]
  • QImaging introduces new CCD cameras for microscopy with modern software to streamline image capture
    QImaging, a manufacturer of scientific cameras for life science and OEM applications, introduces a new series of Retiga CCD cameras, accompanied by QImaging’s new acquisition software to deliver high-performance tools for microscopy and imaging to researchers at an affordable price. The new QImaging Retiga R1, Retiga R3 and Retiga R6 cameras offer valuable technical features […]
  • Sigma-Aldrich announces a new certification to aid IVD customers
    Sigma-Aldrich, a life science and high technology company, announced the company has received ISO 13485 certification for expanded quality assurance capabilities at its Dekalb and Barton facilities located in St. Louis. The certification extends Sigma-Aldrich’s ability to manufacture and offer critical raw materials, such as enzymes, proteins and antibodies used in diagnostic assays, and supplies in vitro […]
  • Prescribing the right power supply: Important considerations for using batteries to power medical devices
    Sol Jacobs, VP and General Manager, Tadiran Batteries Medical technology is advancing rapidly, requiring increasingly sophisticated power management solutions, especially when then the device needs to be self-powered. Battery-powered medical devices encompass a wide range of applications, including surgical drills, power tools, automatic external defibrillators (AEDs), infusion pumps, bone growth stimulators and other wearable devices, […]
  • Qosina announces the launch of its e-commerce website
    Qosina is pleased to announce the launch of its e-commerce website, making it easier to purchase thousands of medical device components from stock inventory. Visitors coming to the new will discover a new look and feel and improvements with every click including: · Easy navigation: A new category structure that mirrors the print catalog […]
  • Athermal laser machining for medical implants is the topic of Norman Noble’s latest whitepaper
    Thermal lasers have achieved extraordinary results in microprecision manufacturing of medical implants and devices the past 20 years. Devices we take for granted today, such as vascular stents, could not be produced without the technology; however, there are still significant limitations on what medical implant and device manufactures can produce using thermal lasers. One major issue […]
  • Sealevel announces the SeaISO family of USB isolators
    Sealevel announces the SeaISO family of USB isolators with 4 kV of medical-grade optical isolation between the host computer and connected USB equipment. SeaISO USB isolators are UL Recognized, in accordance with EN60601-1 3rd Edition, and protect both the power and data lines of connected USB devices from harmful ground loops, damaging transients and surges […]
  • The 21st Century Cures Discussion document recently released to the public
    It has been reported that among the 10,000 known diseases, 7,000 of which are considered rare, there are treatments for only 500. According to Dr. Francis Collins, Director of the National Institutes of Health (NIH), it now takes “around 14 years and $2 billion or more” to develop a new drug and “more than 95% […]

Leave a Reply